Drug intelligence / Profile preview

ACC085

Development stage: Unknown
Lead developer: AIDEA PHARMA
Modality: Small Molecules
Administration: Subcutaneous

Overview

ACC085 is a long-acting, small molecule non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Jiangsu Aidi Pharmaceutical for the pre-exposure prophylaxis (PrEP) of HIV-1 infection. Designed for subcutaneous administration, ACC085 aims to provide a sustained preventive solution against HIV-1 transmission, potentially offering a more convenient alternative to daily oral PrEP regimens. The drug is currently undergoing Phase 1 clinical trials in China to evaluate its safety, tolerability, pharmacokinetics, and effects on the QTc interval in healthy adults.

Other names: ACC085 InjectionACC-085 InjectionACC 085 Injection

Targets

p24 (HIV-1 capsid protein p24)

Beyond the preview

Go deeper on ACC085.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACC085.

Explore the full profile